Novo Nordisk to submit obesity tablet for approval this year
A phase IIIa study shows oral semaglutide can induce a 15.1% weight loss in a 50mg dose, informs the drugmaker.
by christopher due karlsson, translated by daniel pedersen
On Monday, Danish drugmaker Novo Nordisk reported data from a phase IIIa of oral semaglutide in a 50mg dose. According to a press release, the study showed an average weight loss of 17.4% in participants who completed the full duration of the study, 68 weeks.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk expects Wegovy limits to last "some months"
For subscribers
High demand makes Novo Nordisk hit the brakes on Wegovy
For subscribers
